Holger N Lode (Holger Lode)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 24

Top Venues

Cancers

Clinical cancer research : an official journal of the American Association for Cancer Research

Oncoimmunology

Healthcare (Basel, Switzerland)

University Medicine Greifswald

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University Medicine Greifswald Sep 01 2009

Germany

Professor and Chair of Pediatrics :: Pediatric Hematology and Oncology

Publications

Lena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, Rita Pfeifer, Michael Aigner, Bianca Altvater, Sascha Kretschmann, Simon Völkl, Jordan Hartley, Celine Dreger, Katja Petry, Andreas Bosio, Angelika von Döllen, Wolfgang Hartmann, Holger N Lode, Dennis Görlich, Andreas Mackensen, Melanie Jungblut, Axel Schambach, Hinrich Abken, Claudia Rossig
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Lena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, Rita Pfeifer, Michael Aigner, Bianca Altvater, Sascha Kretschmann, Simon Völkl, Jordan Hartley, Celine Dreger, Katja Petry, Andreas Bosio, Angelika von Döllen, Wolfgang Hartmann, Holger N Lode, Dennis Görlich, Andreas Mackensen, Melanie Jungblut, Axel Schambach, Hinrich Abken, Claudia Rossig
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (16) (2024)
Lena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, Rita Pfeifer, Michael Aigner, Bianca Altvater, Sascha Kretschmann, Simon Völkl, Jordan Hartley, Celine Dreger, Katja Petry, Andreas Bosio, Angelika von Döllen, Wolfgang Hartmann, Holger N Lode, Dennis Görlich, Andreas Mackensen, Melanie Jungblut, Axel Schambach, Hinrich Abken, Claudia Rossig
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Tabea Troschke, Aleksandra Wieczorek, Konrad Kulinski, Tomasz Ociepa, Karolina Zielezinska, Holger N Lode, Tomasz Urasinski
Pediatric Hematology and Oncology Center Integrated by Telemedicine: Experience, Challenges and First Results of a Cross Border Network. Healthcare (Basel, Switzerland) 11 (10) (2023)
Holger N Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz, Aleksandra Wieczorek
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers 15 (13) (2023)
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus, Holger N Lode
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers 15 (3) (2023)
Tim Flaadt, Martin Ebinger, Malin Schreiber, Ruth L Ladenstein, Thorsten Simon, Holger N Lode, Barbara Hero, Martin U Schuhmann, Jürgen Frank Schäfer, Frank Paulsen, Beate Timmermann, Angelika Eggert, Peter Lang
Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse. Journal of clinical medicine 12 (19) (2023)
Holger N Lode, Karoline Ehlert, Stephanie Huber, Sascha Troschke-Meurer, Nikolai Siebert, Maxi Zumpe, Hans Loibner, Ruth Lydia Ladenstein
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. British journal of cancer (2023)
Niklas Abele, Soenke Langner, Ute Felbor, Holger N Lode, Norbert Hosten
Quantitative Diffusion-Weighted MRI of Neuroblastoma. Cancers 15 (7) (2023)
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus, Holger N Lode
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers 15 (3) (2023)
Tim Flaadt, Ruth Lydia Ladenstein, Martin Ebinger, Holger N Lode, Helga Björk Arnardóttir, Ulrike Pötschger, Wolfgang Schwinger, Richard P Meisel, Friedhelm R Schuster, Michaela Döring, Peter F Ambros, Manon Queudeville, Joerg Fuchs, Steven W Warmann, Jürgen Frank Schäfer, Christian Seitz, Patrick Schlegel, Ines B Brecht, Ursula Holzer, Tobias Feuchtinger, Thorsten Simon, Johannes H Schulte, Angelika Eggert, Heiko-Manuel Teltschik, Toni Illhardt, Rupert Handgretinger, Peter Lang
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner, Holger N Lode
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14 (23) (2022)
Nikolai Siebert, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse, Holger N Lode
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD 2 Antibody Dinutuximab Beta. Cancers 14 (19) (2022)
Sascha Marx, Fabian Wilken, Lea Miebach, Mikael Ispirjan, Frederik Kinnen, Sebastian Paul, Sandra Bien-Möller, Eric Freund, Jörg Baldauf, Steffen Fleck, Nikolai Siebert, Holger N Lode, Andreas Stahl, Bernhard H Rauch, Stephan Singer, Christoph Ritter, Henry W S Schroeder, Sander Bekeschus
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients. Cancers 14 (23) (2022)
Sascha Marx, Fabian Wilken, Lea Miebach, Mikael Ispirjan, Frederik Kinnen, Sebastian Paul, Sandra Bien-Möller, Eric Freund, Jörg Baldauf, Steffen Fleck, Nikolai Siebert, Holger N Lode, Andreas Stahl, Bernhard H Rauch, Stephan Singer, Christoph Ritter, Henry W S Schroeder, Sander Bekeschus
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients. Cancers 14 (23) (2022)
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner, Holger N Lode
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14 (23) (2022)
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N Lode
Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers 14 (8) (2022)
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Hans Loibner, Oliver Mutschlechner, Holger N Lode
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments. Cancers 14 (23) (2022)
Sascha Marx, Fabian Wilken, Lea Miebach, Mikael Ispirjan, Frederik Kinnen, Sebastian Paul, Sandra Bien-Möller, Eric Freund, Jörg Baldauf, Steffen Fleck, Nikolai Siebert, Holger N Lode, Andreas Stahl, Bernhard H Rauch, Stephan Singer, Christoph Ritter, Henry W S Schroeder, Sander Bekeschus
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients. Cancers 14 (23) (2022)
Sascha Marx, Fabian Wilken, Isabel Wagner, Madlen Marx, Sascha Troschke-Meurer, Maxi Zumpe, Sandra Bien-Moeller, Martin Weidemeier, Joerg Baldauf, Steffen K Fleck, Bernhard H Rauch, Henry W S Schroeder, Holger N Lode, Nikolai Siebert
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of neuro-oncology 147 (3) (2020)
Sascha Troschke-Meurer, Nikolai Siebert, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Oliver Mutschlechner, Hans Loibner, Ruth Ladenstein, Holger N Lode
Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. Oncoimmunology 8 (12) (2019)
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Juliet Gray, Alberto Garaventa, Carla Manzitti, Shifra Ash, Thomas Klingebiel, James Beck, Victoria Castel, Dominique Valteau-Couanet, Hans Loibner, Ruth Ladenstein, Holger N Lode
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers 10 (10) (2018)
Kiraz Ceylan, Luciana J Jahns, Bjoern N Lode, Karoline Ehlert, Silke Kietz, Sascha Troschke-Meurer, Nikolai Siebert, Holger N Lode
Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma. Pediatric blood & cancer 65 (6) (2018)
Ina Mueller, Karoline Ehlert, Stefanie Endres, Lena Pill, Nikolai Siebert, Silke Kietz, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Evelyne Janzek, Norbert Hosten, Andreas Zinke, Winfried Barthlen, Emine Varol, Hans Loibner, Ruth Ladenstein, Holger N Lode
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. mAbs 10 (1) (2017)

Holger N Lode.css-eqlu8i{font-size:small;padding-left:4px;} (Holger Lode)

Publication Activity (10 Years)

Top Topics

Top Venues

Holger N Lode (Holger Lode)